CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
tralokinumab cohort 1 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02036580
NCT02036580Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis

AstraZeneca·interventional·Posted Jan 15, 2014·Updated Feb 23, 2017

In Brief

A Phase 2 clinical trial evaluating tralokinumab cohort 1, tralokinumab cohort 2, and 1 other intervention for Idiopathic Pulmonary Fibrosis. Completed, enrolled 37 participants across 5 sites.

Detailed Summary

The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesJapan
CollaboratorsMedImmune LLC

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 15, 2014
Enrollment StartJan 1, 2014
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.5 years ago

Interventions

tralokinumab cohort 1biological

Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor

tralokinumab cohort 2biological

Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor

Placeboother